Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Short term Debt (2016 - 2025)

Immucell's Short term Debt history spans 16 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 7.52% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 7.52%, while the annual FY2025 figure was $1.6 million, 7.52% up from the prior year.
  • Short term Debt reached $1.6 million in Q4 2025 per ICCC's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.6 million in Q4 2025 to a low of $767517.0 in Q1 2021.
  • Average Short term Debt over 5 years is $1.2 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Short term Debt: fell 25.84% in 2021, then skyrocketed 46.12% in 2024.
  • A 5-year view of Short term Debt shows it stood at $812207.0 in 2021, then grew by 27.98% to $1.0 million in 2022, then skyrocketed by 37.46% to $1.4 million in 2023, then increased by 4.82% to $1.5 million in 2024, then increased by 7.52% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Short term Debt are $1.6 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025).